YOLFTbeta
Autobio Diagnostics Co Ltd

Autobio Diagnostics Co Ltd

603658 · SHG · Healthcare / Medical Devices

38.30CNY+0.08 (+0.21%)

Price History

Full chart

Market Stats

Previous Close38.22
Open38.86
Day Range37.84 – 38.97
52-Week Range28.18 – 39.80
Volume3.46M
Market Cap19.47B
P/E (TTM)19.81
Forward P/E0.00
EPS1.72
Dividend Yield3.84%
Beta-0.02
50-Day Avg32.97
200-Day Avg33.84

About

Autobio Diagnostics Co., Ltd. engages in the research and development, production, marketing, sale, and service of clinical diagnostic products in China and internationally. The company offers immunoassay, biochemistry, and microbiology products; reagents and instruments; and technical and support, and training services, as well as engages in biology research and development activities. Its immunoassay products consist of AutoLumo S900 and AutoLumo A1860 that provides user experience for small and medium size labs; AutoLumo A6200/A6600, an automatic immunoassay analyzer; AutoLumo A2000 Plus, an automated chemiluminescence immunoassay analyzer; PHOmo microplate readers; LUmo microplate luminometers; and iWO-960 microplate washers. The company's microbiology products include AutoMic-I60 for microbial identification and antibiotic susceptibility testing; AutoStreak S1800, a microbial sample pretreatment system; Autof T series and MALDI-TOF MS system for the identification of pathogenic bacteria; AutoMimo 1200, an instrument for improving pipetting efficiency and optimize workflow in the lab; BC60, an automatic blood culture instrument; and BC120, an automated bacterial culturing and detection. It also provides blood culture bottles and mycoplasma TIES reagents; AutoMolec 1600, an integrated and automated molecular diagnostics analyzer; AutoMolec 3000, an in vitro molecular detection instrument; Ci-120x and Ci-310 benchtop coagulation analyzers; and Autolas Bi 1000, Autolas Bi2600, AutoChem B861, and AutoChem B2000 automated biochemistry analyzers, as well as Autolas X series, and Autolas B series. The company was formerly known as Lifeclone Diagnostics Co., Ltd. and changed its name to Autobio Diagnostics Co., Ltd. in 2003. Autobio Diagnostics Co., Ltd. was founded in 1998 and is headquartered in Zhengzhou, China. Autobio Diagnostics Co., Ltd. is a subsidiary of Zhengzhou Autobio Co., Ltd.

Company Details

  • SectorHealthcare
  • IndustryMedical Devices
  • CEOMr. Zeng Li Yang
  • Employees5.70K
  • HeadquartersNo. 199, Jingkai 15th Street, Zhengzhou, China, 450016, China
  • Websitehttps://www.autobio.com.cn

Leadership

  • Mr. Zeng Li YangGM & Director · b. 1968
  • Ms. Wei LiuEmployee Representative Director & Director of Administrative Center · b. 1976
  • Mr. Rui Kuan FangDeputy GM & Secretary of the Board of Directors · b. 1971
  • Mr. Xue Wei WuDeputy GM & Director · b. 1967
  • Mr. Guang Yu FuExecutive Deputy GM & Director · b. 1969
  • Ms. Chao Jie FengDirector · b. 1978
  • Mr. Rui Feng ZhangExecutive Deputy GM & Director · b. 1975
  • Dongdong WangChief Financial Officer

Financials

Income Statement

Currency: CNY2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue211.84M318.15M409.36M563.30M716.49M980.22M1.40B1.93B2.68B2.98B3.77B4.44B4.44B4.47B4.23B
Growth (%)-+50.18%+28.67%+37.60%+27.20%+36.81%+42.84%+37.82%+38.85%+11.15%+26.45%+17.94%+0.05%+0.62%-5.47%
Cost of Revenue59.90M92.06M120.41M151.70M195.12M274.62M455.24M659.42M911.39M1.22B1.54B1.84B1.61B1.58B1.45B
Gross Profit151.95M226.09M288.96M411.59M521.37M705.61M944.90M1.27B1.77B1.76B2.22B2.60B2.83B2.89B2.77B
Gross Margin71.73%71.07%70.59%73.07%72.77%71.98%67.49%65.83%65.99%59.17%58.99%58.47%63.73%64.61%65.64%
Operating Expense83.82M120.32M154.46M178.64M209.34M311.17M438.73M616.32M873.81M905.72M1.15B1.30B1.47B1.64B1.62B
Operating Income68.12M105.77M134.50M232.95M312.03M394.44M506.18M653.94M894.24M856.37M1.08B1.30B1.37B1.25B1.15B
Operating Margin32.16%33.25%32.86%41.35%43.55%40.24%36.15%33.89%33.37%28.76%28.58%29.19%30.73%27.86%27.31%
EBITDA75.33M116.93M151.83M261.38M356.88M462.48M602.42M794.92M1.08B1.08B1.34B1.54B1.64B1.62B1.70B
EBITDA Margin35.56%36.75%37.09%46.40%49.81%47.18%43.03%41.19%40.41%36.33%35.59%34.76%36.96%36.15%40.25%
Net Income61.15M96.12M124.08M208.22M278.03M349.76M446.56M562.57M774.16M747.79M973.66M1.17B1.22B1.19B1.07B
Net Income Margin28.87%30.21%30.31%36.96%38.80%35.68%31.89%29.15%28.89%25.11%25.85%26.28%27.40%26.71%25.27%
R&D21.41M33.86M47.66M58.11M64.51M103.88M142.68M212.73M311.91M342.80M480.96M568.48M656.13M731.93M555.12M
R&D as % of Total Revenue10.11%10.64%11.64%10.32%9.00%10.60%10.19%11.02%11.64%11.51%12.77%12.80%14.77%16.37%13.13%
Interest Expense28.12K0171.47K173.65K255.10K922.64K1.06M6.43M24.72M30.01M13.02M21.93M25.36M22.87M13.96M
Interest Expense % of Total Revenue0.01%0.00%0.04%0.03%0.04%0.09%0.08%0.33%0.92%1.01%0.35%0.49%0.57%0.51%0.33%

Balance Sheet

Currency: CNY2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets196.32M280.25M410.42M652.03M945.56M1.82B2.19B2.66B4.26B8.14B9.23B10.47B11.55B11.88B12.29B
Total Liabilities39.36M46.41M70.00M151.08M227.01M176.52M497.85M690.69M1.62B1.55B1.83B2.56B2.89B3.18B3.27B
Total Equity156.96M233.84M340.42M500.94M718.55M1.64B1.67B1.93B2.56B6.48B7.28B7.78B8.54B8.62B8.93B
Cash16.89M45.40M50.76M113.51M196.23M56.21M26.94M57.61M136.88M327.55M769.40M1.14B1.49B465.37M592.27M
Total Debt---33.36M95.71M-39.00M96.89M794.89M200.14M236.07M132.54M367.94M253.01M-
Net Debt-16.89M-45.40M-50.76M-80.15M-100.53M-56.21M12.06M39.28M658.00M-127.41M-533.32M-1.01B-1.12B-212.36M-

Cash Flow

Currency: CNY2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow50.59M69.32M103.22M256.93M308.63M415.82M481.73M653.73M842.89M994.71M1.46B1.56B1.47B1.31B1.34B
Investing Cash Flow-56.14M-23.31M-76.18M-179.04M-222.50M-1.03B-121.03M-345.57M-1.23B-3.48B-510.81M-978.66M-787.22M-1.19B-
Financing Cash Flow-13.77M-17.50M-21.44M-14.68M-3.24M477.06M-388.91M-276.56M470.97M2.68B-502.35M-218.26M-337.01M-1.16B-
Capital Expenditure42.84M28.14M76.32M179.06M221.81M237.42M455.17M410.17M762.07M1.12B1.07B938.32M900.42M664.40M604.30M
Free Cash Flow7.75M41.18M26.91M77.86M86.82M178.40M26.57M243.55M80.81M-120.67M395.39M620.10M569.44M644.88M737.38M
Dividends Paid13.28M17.50M19.99M48.04M65.29M3.76M424.84M305.94M336.00M387.54M383.33M418.94M479.12M623.38M726.68M
FCF to OCF15.33%59.40%26.07%30.31%28.13%42.90%5.51%37.26%9.59%-12.13%27.06%39.79%38.74%49.25%54.96%
Dividend Paid to FCF171.25%42.50%74.29%61.69%75.20%2.11%1599.18%125.61%415.78%-321.16%96.95%67.56%84.14%96.67%98.55%

Earnings

Report DateOct 26, 2016Mar 3, 2017Apr 25, 2017Aug 2, 2017Oct 27, 2017Mar 28, 2018Apr 25, 2018Aug 2, 2018Oct 30, 2018Mar 27, 2019Apr 29, 2019Aug 8, 2019Oct 28, 2019Mar 28, 2020Apr 28, 2020Aug 28, 2020Oct 29, 2020Apr 22, 2021Aug 17, 2021Oct 25, 2021Mar 9, 2022Apr 26, 2022Aug 17, 2022Oct 25, 2022Dec 31, 2022Apr 20, 2023Aug 17, 2023Oct 25, 2023Feb 20, 2024Apr 18, 2024Aug 20, 2024Oct 25, 2024Apr 17, 2025
EPS Estimate----0.370.35--------0.35---0.430.580.440.440.340.620.490.490.560.930.530.480.560.65-
EPS Actual0.200.170.120.230.480.230.180.280.300.280.220.360.400.430.430.320.430.540.320.520.440.410.500.630.460.460.520.590.550.540.510.550.42
Surprise----29.73%-35.66%--------22.86%----25.58%-10.34%0.00%-6.82%47.06%1.61%-6.12%-6.12%-7.14%-36.56%3.77%12.50%-8.93%-15.38%-
TimingAfter-hoursAfter-hoursAfter-hoursPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-market-After-hoursPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-marketAfter-hours-Pre-marketAfter-hoursPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-market

Key Statistics & Ratios

Market Cap19.47B
Enterprise Value18.48B
Trailing P/E19.81
Forward P/E0.00
Price / Sales4.61
Price / Book2.27
EPS1.72
Book Value15.18
Revenue (TTM)4.22B
Gross Profit (TTM)2.79B
EBITDA1.47B
Profit Margin23.54%
Operating Margin26.53%
Return on Equity11.67%
Return on Assets5.46%
Shares Outstanding571.42M
Shares Float160.86M
Beta-0.02
Dividend Yield3.84%
Dividend Rate1.31
Payout Ratio76.16%

Dividends

20231×
0.80Jun 12, 2023
20221×
0.72Jun 20, 2022
20211×
0.85May 27, 2021
20201×
0.69Jun 11, 2020
20191×
0.62May 8, 2019
20181×
0.55May 8, 2018
20172×
0.28Sep 13, 20170.50Apr 13, 2017

Stock Splits

  • May 27, 202113:10